X0206 3 2022-12-21 0 0001178879 AMICUS THERAPEUTICS, INC. FOLD 0001569225 Castelli Jeff 3675 MARKET STREET PHILADELPHIA PA 19104 0 1 0 0 Chief Development Officer Common Stock 304255 D Stock Options (right to buy) 12.28 2025-06-01 Common Stock 50000 D Stock Options (right to buy) 9.03 2026-01-04 Common Stock 50000 D Stock Options (right to buy) 15.67 2028-01-03 Common Stock 39762 D Stock Options (right to buy) 10.04 2029-01-02 Common Stock 82644 D Stock Options (right to buy) 9.55 2030-01-02 Common Stock 107575 D Stock Options (right to buy) 21.78 2031-01-04 Common Stock 46396 D Stock Options (right to buy) 12.11 2032-01-03 Common Stock 108266 D Includes 161,910 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Amicus common stock. All of the options in this row are fully vested and exercisable as of December 21, 2022. The options reported in this row were granted on January 2, 2019 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 80,896 of such options were fully vested and exercisable and 1,748 remained unvested. The options reported in this row were granted on January 2, 2020 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 78,436 of such options were fully vested and exercisable and 29,139 remained unvested. The options reported in this row were granted on January 4, 2021 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 22,225 of such options were fully vested and exercisable and 24,171 remained unvested. The options reported in this row were granted on January 3, 2022 and will become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 0 of such options were fully vested and exercisable and 108,266 remained unvested. /s/ Christian Formica, Attorney-in-Fact 2022-12-30